Mirati Therapeutics, Inc. (MRTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mirati Therapeutics, Inc. (MRTX) trades at $58.70 with AI Score 53/100 (Grade B). Mirati Therapeutics, Inc. is a clinical-stage oncology company focused on developing therapies for genetic and immunological drivers of cancer. Market cap: $4.12B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for MRTX: MRTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MRTX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
MRTX: 3/7 perspectives are bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Mirati Therapeutics, Inc. (MRTX) Healthcare & Pipeline Overview
Mirati Therapeutics, Inc. is a clinical-stage biotechnology firm specializing in oncology, particularly known for its KRAS inhibitor programs targeting non-small cell lung, colorectal, and pancreatic cancers. The company's focus on innovative therapies positions it within a competitive landscape of personalized medicine.
What Is the Investment Thesis for MRTX?
Mirati Therapeutics presents a compelling investment case centered on its innovative oncology pipeline, particularly its KRAS inhibitor programs. The company's lead candidate, adagrasib (MRTX849), targets the KRAS G12C mutation, prevalent in NSCLC, colorectal, and pancreatic cancers, offering significant market potential. Positive clinical trial data and potential regulatory approvals for adagrasib could drive substantial revenue growth. Sitravatinib, another key asset, is in Phase 3 trials and could further diversify the company's revenue streams. However, the company's high profit margin of -5957.4% indicates substantial ongoing R&D expenses, and competition in the oncology space poses a risk. Successful commercialization and pipeline expansion are critical for long-term value creation. Upcoming clinical trial results and regulatory milestones serve as key catalysts.
Based on FMP financials and quantitative analysis
MRTX Key Highlights
- Market Cap of $4.12B reflects investor confidence in Mirati's pipeline and potential for future growth in the oncology market.
- Gross Margin of 95.2% indicates strong pricing power and efficient manufacturing processes for its products.
- Beta of 0.77 suggests lower volatility compared to the overall market, potentially making it a more stable investment.
- Focus on KRAS inhibitors positions Mirati at the forefront of targeted cancer therapies, addressing a significant unmet medical need.
- Collaboration with BeiGene, Ltd. expands Mirati's global reach and commercialization capabilities for Sitravatinib.
Who Are MRTX's Competitors?
MRTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ISEE IVERIC bio, Inc. | $39.95 | +0.38% | $5.51B | 47 |
| CBAY CymaBay Therapeutics | $32.48 | +0.03% | $3.73B | 59 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MRTX's Key Strengths?
- Innovative KRAS inhibitor technology.
- Strong pipeline of product candidates.
- Experienced management team.
- Strategic collaborations with leading companies.
What Are MRTX's Weaknesses?
- High R&D expenses.
- Reliance on clinical trial success.
- Competition from other biotechnology and pharmaceutical companies.
- Negative profit margin.
What Could Drive MRTX Stock Higher?
- Data readouts from ongoing clinical trials of adagrasib in various cancer types.
- Potential regulatory submissions and approvals for adagrasib and sitravatinib.
- Expansion of strategic collaborations and partnerships.
- Advancement of preclinical programs into clinical development.
What Are the Key Risks for MRTX?
- Negative return on equity (-61.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $3.4M recently.
- Clinical trial failures or setbacks.
- Regulatory delays or rejections.
- Competition from other biotechnology and pharmaceutical companies.
- High R&D expenses and cash burn.
- Patent expirations and loss of exclusivity.
What Are the Growth Opportunities for MRTX?
- Expansion of Adagrasib (MRTX849) Indications: Adagrasib, a KRAS G12C inhibitor, has the potential to expand beyond NSCLC to other cancer types with the KRAS G12C mutation, such as colorectal and pancreatic cancers. The market for KRAS G12C inhibitors is estimated to reach billions of dollars, and successful clinical trials in these additional indications could significantly increase Mirati's revenue. Timeline: Ongoing clinical trials with potential data readouts in the next 1-2 years.
- Advancement of Sitravatinib: Sitravatinib, a spectrum-selective kinase inhibitor, is currently in Phase 3 clinical trials for NSCLC. Positive trial results and subsequent regulatory approval could provide a significant revenue stream. The NSCLC market is substantial, and a successful commercial launch of Sitravatinib could contribute significantly to Mirati's growth. Timeline: Phase 3 trial results expected within the next year, with potential regulatory submission shortly after.
- Development of KRAS G12D Inhibitor Program: Mirati's preclinical KRAS G12D inhibitor program represents a future growth opportunity. KRAS G12D is another common KRAS mutation, and a successful inhibitor could address a significant unmet need. The market potential for KRAS G12D inhibitors is substantial, offering long-term growth prospects. Timeline: Preclinical development ongoing, with potential for clinical trials in the next 2-3 years.
- Strategic Collaborations and Partnerships: Mirati can pursue strategic collaborations and partnerships to expand its pipeline and commercial reach. Collaborations with other biotechnology and pharmaceutical companies can provide access to new technologies, funding, and markets. These partnerships can accelerate the development and commercialization of Mirati's product candidates. Timeline: Ongoing, with potential for new collaborations in the near term.
- Expansion into New Therapeutic Areas: While Mirati is primarily focused on KRAS inhibitors, the company can explore opportunities to expand into other therapeutic areas within oncology. This could involve developing therapies for other genetic drivers of cancer or exploring new approaches such as immunotherapy. Diversifying its pipeline can reduce risk and create new growth opportunities. Timeline: Long-term, with potential for new programs in the next 3-5 years.
What Opportunities Does MRTX Have?
- Expansion of adagrasib indications.
- Advancement of sitravatinib.
- Development of new cancer therapies.
- Strategic acquisitions and partnerships.
What Threats Does MRTX Face?
- Clinical trial failures.
- Regulatory setbacks.
- Competition from biosimilars.
- Economic downturn.
What Are MRTX's Competitive Advantages?
- Proprietary KRAS inhibitor technology provides a competitive advantage.
- Strong patent protection for its product candidates.
- Expertise in developing targeted cancer therapies.
- Established collaborations with leading research institutions and pharmaceutical companies.
What Does MRTX Do?
Founded in 1995 and headquartered in San Diego, California, Mirati Therapeutics, Inc. is dedicated to transforming the lives of patients with cancer by developing innovative therapies that target the genetic and immunological drivers of the disease. The company's evolution has been marked by a commitment to addressing unmet needs in oncology, particularly in areas with limited treatment options. Mirati's pipeline features a range of product candidates, including MRTX849 (adagrasib), a KRAS G12C inhibitor, which is in Phase 1/2 clinical trials for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers. Additionally, the company is developing Sitravatinib, an investigational spectrum-selective kinase inhibitor currently in Phase 3 clinical trials for NSCL cancer treatment. Furthermore, Mirati has a KRAS G12D inhibitor program in preclinical development, expanding its focus on KRAS mutations. The company collaborates with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib, enhancing its global reach. Mirati's strategic focus on precision oncology and targeted therapies aims to provide more effective and personalized treatment options for cancer patients.
What Products and Services Does MRTX Offer?
- Develops targeted therapies for cancer.
- Focuses on addressing genetic and immunological promoters of cancer.
- Creates KRAS inhibitors to treat non-small cell lung, colorectal, and pancreatic cancers.
- Develops spectrum-selective kinase inhibitors for cancer treatment.
- Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
- Collaborates with other companies to develop and commercialize its therapies.
- Engages in preclinical research to discover new cancer treatments.
How Does MRTX Make Money?
- Develops and patents novel cancer therapies.
- Conducts clinical trials to gain regulatory approval.
- Commercializes approved therapies directly or through partnerships.
- Generates revenue through sales of its approved therapies and licensing agreements.
What Industry Does MRTX Operate In?
Mirati Therapeutics operates within the dynamic and competitive biotechnology industry, specifically focused on oncology. The industry is characterized by rapid innovation, high R&D spending, and stringent regulatory requirements. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Mirati's focus on KRAS inhibitors places it in a competitive landscape with other companies developing targeted therapies. Key trends include personalized medicine, immunotherapy, and gene editing. The company's success depends on its ability to develop and commercialize innovative therapies that address unmet needs in oncology.
Who Are MRTX's Key Customers?
- Cancer patients in need of targeted therapies.
- Oncologists and other healthcare professionals who prescribe cancer treatments.
- Hospitals and cancer centers that administer cancer therapies.
- Pharmaceutical companies that partner with Mirati to develop and commercialize its products.
ROE -62%Key Financial Metrics
Return on equity for Mirati Therapeutics, Inc. stands at -61.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -61.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -14.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.96 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -22.4%, the inverse of the P/E and a quick read on earnings relative to price.
Mirati Therapeutics, Inc. (MRTX) Valuation Context
Valued at $4.12B, MRTX is classified as a mid-cap stock. Relative to its peer group, MRTX's quantitative score of 53/100 is below the peer average of 68/100.
Company Profile
Mirati Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Charles M. Baum. MRTX has traded publicly since 2013.
F-Score 3/9Financial Health
Mirati Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 8.58 places it in the safe zone, indicating low near-term bankruptcy risk.
Net sellingInsider Activity
The most recent 12 insider filings for Mirati Therapeutics, Inc. break down as 12 sales and 0 purchases. On net that is roughly 1.5M shares disposed (about $3.4M), a signal worth weighing alongside the fundamentals.
MRTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Mirati's pipeline, indicating potential positive developments ahead.
- Community sentiment has shifted positively, with discussions highlighting the promise of their latest drug trials.
- Analysts are increasingly optimistic about Mirati's innovative therapies, reflecting a growing belief in their market potential.
- The company's strategic partnerships have enhanced its credibility and visibility in the biotech space, attracting more investor interest.
Bear Case
- Concerns over regulatory hurdles persist, with some investors questioning the approval timelines for Mirati's key products.
- Social media sentiment has shown volatility, with mixed opinions on the sustainability of recent gains in stock price.
- Recent news of competitor advancements has raised fears about Mirati's market positioning and long-term viability.
- Cash burn rates remain a concern, leading to questions about the company's financial health in the near term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MRTX Latest News
No recent news available for MRTX.
MRTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MRTX.
Price Targets
Wall Street price target analysis for MRTX.
MRTX MoonshotScore
What does this score mean?
The MoonshotScore rates MRTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Charles M. Baum
President and Chief Executive Officer
Charles M. Baum serves as the President and Chief Executive Officer of Mirati Therapeutics, Inc. His career spans several decades in the pharmaceutical and biotechnology industries, with a focus on oncology drug development and commercialization. He has held leadership positions at various companies, contributing to the advancement of innovative therapies. Baum's expertise includes clinical development, regulatory affairs, and commercial strategy. He brings a wealth of experience to Mirati, guiding the company's strategic direction and pipeline development.
Track Record: Under Charles Baum's leadership, Mirati Therapeutics has made significant strides in advancing its KRAS inhibitor programs. Key achievements include the progress of adagrasib (MRTX849) through clinical trials and the development of sitravatinib. Baum has overseen strategic collaborations and partnerships, enhancing the company's growth prospects. His focus on innovation and execution has positioned Mirati as a leader in targeted cancer therapies.
What Investors Ask About Mirati Therapeutics, Inc. (MRTX) — Healthcare
What does Mirati Therapeutics, Inc. do?
Mirati Therapeutics, Inc. is a clinical-stage oncology company focused on developing innovative therapies that target the genetic and immunological drivers of cancer. The company's primary focus is on developing KRAS inhibitors, such as adagrasib (MRTX849), which targets the KRAS G12C mutation prevalent in non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. Mirati also develops other targeted therapies, including sitravatinib, a spectrum-selective kinase inhibitor. The company aims to provide personalized treatment options for cancer patients by addressing specific genetic mutations and immunological factors that contribute to tumor growth and progression.
What do analysts say about MRTX stock?
Analyst consensus on Mirati Therapeutics (MRTX) stock reflects a mixed outlook, acknowledging the company's potential in the oncology space while also considering the inherent risks associated with clinical-stage biotechnology companies. Key valuation metrics, such as market capitalization and revenue projections, are closely monitored. Growth considerations include the successful development and commercialization of adagrasib and sitravatinib, as well as the expansion of the company's pipeline. Analyst ratings and price targets vary, reflecting different perspectives on the company's prospects and potential challenges. The company's financial performance, clinical trial results, and regulatory milestones are closely watched by analysts and investors.
What are the main risks for MRTX?
Mirati Therapeutics faces several key risks inherent to the biotechnology industry and specific to its business model. Clinical trial failures or setbacks pose a significant risk, as the company's pipeline relies on the successful development of its product candidates. Regulatory delays or rejections can also impact the company's timeline and commercial prospects. Competition from other biotechnology and pharmaceutical companies developing similar therapies is another risk. High R&D expenses and cash burn are ongoing concerns, requiring the company to manage its finances carefully. Patent expirations and loss of exclusivity could also impact the company's long-term revenue potential. These risks are carefully monitored by investors and analysts.
How does Mirati Therapeutics, Inc. navigate regulatory approval processes?
Mirati Therapeutics navigates regulatory approval processes by adhering to stringent guidelines set forth by regulatory agencies such as the FDA in the United States. The company's strategy involves comprehensive preclinical and clinical studies to demonstrate the safety and efficacy of its product candidates. Mirati maintains close communication with regulatory agencies throughout the development process, seeking guidance and feedback to ensure compliance. The company's regulatory track record includes successful interactions with the FDA, and it is actively pursuing regulatory approvals for its lead product candidates, including adagrasib and sitravatinib. A robust compliance strategy is essential for navigating the complex regulatory landscape and securing timely approvals for its therapies.
How does Mirati Therapeutics, Inc. manage patent expiration risks?
Mirati Therapeutics manages patent expiration risks through a multi-faceted approach that includes actively seeking patent protection for its innovative technologies and product candidates. The company's patent strategy involves filing patent applications for new chemical entities, formulations, and methods of use. Mirati also engages in lifecycle management strategies to extend the exclusivity of its products, such as developing new formulations or indications. The company monitors the competitive landscape and actively defends its intellectual property rights. While patent expiration is an inevitable part of the pharmaceutical industry, Mirati's proactive approach aims to maximize the commercial lifespan of its products and mitigate the impact of potential biosimilar competition.
What are the key factors to evaluate for MRTX?
Mirati Therapeutics, Inc. (MRTX) holds an AI score of 53/100 (moderate). Not financial advice.
How frequently does MRTX data refresh on this page?
MRTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MRTX's recent stock price performance?
Mirati Therapeutics, Inc. (MRTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative KRAS inhibitor technology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-05-10 and may be subject to change.
- Clinical trial outcomes are inherently uncertain and can impact company prospects.